Aberrant PI3K/AKT activation has been reported in 50% to 80% of acute myeloid leukemias (AML), up to 88% of acute T-lymphoblastic leukemias (ALL), and in chronic myeloid leukemia (CML) [5–7]. Here, AKT1 is linked to acute myeloid leukemia.